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Introduction
At present, disease management of patients with type 2 diabe-
tes (T2DM) is mainly focussed on glucose regulation, blood 
pressure and lipid control, prevention of diabetic ulcers, and 
the early detection of specific micro-vascular problems, typi-
cally albuminuria and retinopathy. Despite increased empha-
sis on lipid and blood pressure control in the last decade, 
premature cardiovascular diseases remain the main cause of 
mortality in patients with T2DM [1]. It is therefore surpris-
ing that current disease management programs do not yet 
prioritise early detection of cardiovascular diseases.
In view of this, we hypothesised that especially older 
patients with T2DM may have unsuspected and unrecog-
nised heart failure. Especially heart failure with preserved 
ejection fraction (HFpEF) is expected to be highly preva-
lent, because in the early stages of this subtype of heart fail-
ure, symptoms often only occur after exercise, and signs of 
fluid retention can be inconspicuous. The risk of remain-
ing undetected and being wrongly labelled as e.g. chronic 
obstructive pulmonary disease (COPD) is high for HFpEF, 
the more because echocardiography is not readily available 
in primary care, while echocardiography is essential for 
establishing the diagnosis of HFpEF.
Heart failure in type 2 diabetes in the Netherlands
Our group showed that the prevalence of previously 
unknown heart failure in patients with T2DM aged ≥ 60 is 
high (27.7 %), steeply rises with age, and is overall higher 
in women than in men (31.0 vs. 24.8 %, respectively). 
The majority (83 %; i.e. 22.9 % of all T2DM patients 
aged ≥ 60 years) had HFpEF, while 17 % (i.e. 4.8 % of all 
T2DM patients ≥ 60 years) had previously unrecognised 
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Abstract Undetected heart failure appears to be an im-
portant health problem in patients with type 2 diabetes and 
aged ≥ 60 years. The prevalence of previously unknown 
heart failure in these patients is high, steeply rises with age, 
and is overall higher in women than in men. The majority 
of the patients with newly detected heart failure have a pre-
served ejection fraction. A diagnostic algorithm to detect or 
exclude heart failure in these patients with variables from 
the medical files combined with items from history taking 
and physical examination provides a good to excellent ac-
curacy. Annual screening appears to be cost-effective. Both 
unrecognised heart failure with reduced and with preserved 
ejection fraction were associated with a clinically relevant 
lower health status in patients with type 2 diabetes. Also 
the prognosis of these patients was worse than of those 
without heart failure. Existing disease-management pro-
grams for type 2 diabetes pay insufficient attention to early 
detection of cardiovascular diseases, including heart fail-
ure. We conclude that more attention is needed for detec-
tion of heart failure in older patients with type 2 diabetes.
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238 Neth Heart J (2016) 24:237–243
Screening patients with T2DM older than 60 years 
for heart failure
It seems reasonable to distinguish between screening for 
HFrEF and HFpEF, because both the prevalence of unrecog-
nised disease and the availability of evidence-based interven-
tions for reducing morbidity and mortality differ considerably. 
The prevalence is much higher for HFpEF, while convincing 
evidence-based therapy is only available for HFrEF.
When the screening criteria of Wilson and Jungner are 
applied, it seems that most criteria for screening are fulfilled 
for HFrEF, but not for HFpEF (Table 1; [7]). For HFpEF, 
there is much more uncertainty. For example, its natural 
history is less clear, and also the underlying pathophysi-
ological pathways have not been fully elucidated, although 
recently the understanding of possible causal mechanisms 
has increased [8]. Important questions remain, e.g. about the 
exact mechanisms involved in the development of ‘diabetic 
cardiomyopathy’ [9]. Furthermore, there is still an ongo-
ing discussion on the exact echocardiographic criteria that 
should be fulfilled to establish HFpEF, and this hampers the 
diagnosis. Finally, treatment of HFpEF is focused on reduc-
tion of symptoms of fluid overload and comorbid conditions 
[10]. Diuretics are the only option for symptom relief, but 
their prognostic effects have never been adequately evalu-
ated. Other drugs, including beta-blockers, angiotensin-con-
verting-enzyme inhibitors, angiotensin II receptor blockers 
and mineralo-corticoid inhibitors have been tested in ran-
heart failure with reduced ejection fraction (HFrEF) [2]. 
To unmask early disease manifestations we developed a 
diagnostic algorithm to detect or exclude heart failure in 
T2DM patients aged ≥ 60 years [3]. Variables that can easily 
be assessed in the electronic medical files of primary care 
facilities in combination with items from history taking and 
physical examination provided a good to excellent accuracy 
for detection or exclusion of heart failure in such patients 
with a C-statistic of 0.82; 95 % CI 0.79–0.86. We rounded 
the coefficients of the clinical model to the nearest inte-
ger after shrinkage to construct this diagnostic algorithm. 
Variables included were age over 75 (1 point), a history 
of ischaemic heart disease (1 point), a history of transient 
ischaemic attack or stroke (1 point), dyspnoea or fatigue (2 
points), reported ankle oedema or nocturia (1 point), inter-
mittent claudication (1 point), and signs of fluid overload (1 
point). Patients with more than three points have a higher 
risk of heart failure of more than 20 %. Both electrocardiog-
raphy and natriuretic peptides had independent added value 
beyond the clinical model and increased the C-statistic to 
0.86; 95 % CI 0.83–0.89 [3].
Does this make screening cost-effective? Annual screen-
ing for heart failure of patients with T2DM aged ≥ 60 
appears to be cost-effective. A model with information from 
the electronic medical records (age and comorbidities) and 
suggestive symptoms of heart failure performed best for a 
low willingness-to-pay threshold of € 20,000 per quality-
adjusted life-year, a commonly used threshold in Europe. 
The potential cost-effectiveness would be better if convinc-
ing mortality-reducing treatment for HFpEF were to become 
available in the near future [4].
Already at the time of screening, both screen-detected 
HFrEF and HFpEF were associated with a clinically rel-
evant lower health status than patients with T2DM without 
heart failure. This persisted during the 1-year follow-up 
period. Patients with T2DM without screen-detected or 
known heart failure had a similar health status to age- and 
gender-matched subjects from the population at large [4, 5]. 
Patients with T2DM and screen-detected heart failure also 
had a worse prognosis than T2DM patients without such 
a diagnosis. After adjustment for age and gender, the haz-
ard ratio for all-cause mortality was 1.5 (95 % CI 0.8–2.7), 
for cardiac hospitalisations 2.2 (95 % CI 1.5–3.3), and for 
the composite endpoint combining these two 1.8 (95 % CI 
1.3–2.6). The negative prognostic effect was most evident 
in those with HFrEF. The hazard ratio adjusted for age and 
gender for the combined endpoint of all-cause mortality 
and cardiac hospitalisations was 3.7 (95 % CI 2.2–6.3) for 
HFrEF and 1.5 (95 % CI 1.0–2.2) for HFpEF compared 
with those without screen-detected heart failure [6]. Note 
the mean NT-proBNP at diagnosis was significantly higher 
for patients with HFrEF than for patients with HFpEF: 104 
vs. 33 pmol/l respectively; p < 0.001.
Table 1 Principles of early detection of, or screening for disease of 
Wilson and Jungner, 1968, applied to detection of heart failure in pa-
tients with T2DM aged 60 years or over
Criteria met for
HFrEF HFpEF
1. The condition sought should be an important 
health problem
+ +
2. There should be an accepted treatment for the 
disease
+ +/−
3. Facilities for diagnosis and treatment should 
be available
+/- +/−
4. There should be a recognisable latent or early 
symptomatic stage of the disease
+ +/−
5. There should be a suitable test or examination 
for the disease
+ +/−
6. The test should be acceptable to the population + +/−
7. The natural history of the disease should be 
adequately understood
+ +/−
8. There should be an agreed policy on whom to 
treat as patients
+ +/−
9. The total cost of finding a case should be 
economically balanced in relation to medical 
expenditure as a whole
+ −
10. Case-finding should be a continuous process, 
not just a ‘once and for all’ project
+ +/−
HFrEF heart failure with reduced ejection fraction, HFpEF heart 
failure with preserved ejection fraction, + fully met; +/− partly met, 
− does not meet the criterion.
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and this prevents misclassification in other diseases that may 
also cause breathlessness and fatigue, such as COPD. Also, 
the possibility of adequately treating symptoms of breath-
lessness by managing incidental periods of volume overload 
with diuretics should not be undervalued. Finally, one could 
argue that the patient should at least be aware that he or she 
has a condition with a relatively poor prognosis.
Time for a change
In many countries, including the Netherlands, T2DM 
patients are enrolled in disease management programs with 
domised trials in patients with HFpEF, mainly in addition to 
diuretics, but with disappointing results, with at best a sta-
tistically non-significant relative risk reduction on all-cause 
mortality of around 10 % [10]. These results can be further 
‘downgraded’ because a substantial number of the included 
patients had a left ventricular ejection fraction in the range 
of 40–50 %, and many consider this to be HFrEF, and not 
HFpEF. Thus, screening all T2DM patients aged ≥ 60 for 
HFrEF seems more reasonable according to the criteria of 
Wilson and Jungner than screening for HFpEF. Although 
convincing prognostically beneficial therapy for HFpEF is 
currently not yet available, one could argue that detecting 
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for these patients should become aware of the large risk of 
unknown heart failure in T2DM patients aged ≥ 60 years.
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a trained nurse practitioner playing a key role. Such pro-
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